For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don’t just<a class="excerpt-read-more" href=" More ...
Hosted on MSN16h
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are CrucialEli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...
Zacks.com on MSN17h
LLY Rises More Than 4% in a Week: How to Play the StockEli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback